онкология рак

In research AGO-GINECO authors have estimated expediency of addition антрациклинов to a combination карбоплатин паклитаксел. Inclusion эпирубицина has strengthened toxicity of a combination, but has not improved results of therapy [10]. In research SCOTROC comparison available today in our disposal таксанов is made: паклитаксела and доцетаксела [11]. Both preparations in a combination with карбоплатином have shown identical frequency of objective effects and time before progressing. The combination карбоплатин-паклитаксел possessed more expressed нейротоксичностью while карбоплатин-доцетаксел caused development нейтропении is more often. Подробнее...

Researchers from Center MD Anderson in 1998 publish 5-years results of treatment of patients инвазивным cancer I-II of a stage with one-stage reconstruction, also having divided{shared} patients on two groups as executed мастэктомии with one-stage reconstruction - with preservation of a leather{skin} (104 patients) and without (27 patients) [36]. The percent{interest} of local relapses has made accordingly - 6,7 % and 7,4 %, system progressing of illness of 12,5 % against 25,9 % in group standard мастэктомии, parameters безрецидивной and the general{common} survival rate in the first group have made 88,5 % and 80,8 %, and in the second 74,1 % and 55,6 %. Certainly, in the given situation it is possible to think of absence of impartiality of the surgeons choosing methods for treatment of those or other patients when the patient with more worse forecast carried out standard operative interventions. Подробнее...